Does Rallies show Form 4 insider transactions for ORKA?

Yes. Rallies tracks ORKA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ORKA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ORKA. It does not provide personalized investment advice.

ORKA (Oruka Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Oruka Therapeutics, Inc. Common Stock (ORKA) is a publicly traded Healthcare sector company. As of May 21, 2026, ORKA trades at $60.67 with a market cap of $3.52B and a P/E ratio of 0.00. ORKA moved +5.49% today. Year to date, ORKA is +125.71%; over the trailing twelve months it is +471.28%. Its 52-week range spans $5.49 to $91.00. Analyst consensus is strong buy with an average price target of $137.25. Rallies surfaces ORKA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ORKA stock inside the company?

Recent ORKA insider activity includes Agarwal Arjun sold 4.19K, Agarwal Arjun sold 4.60K, Agarwal Arjun sold 800, Agarwal Arjun sold 700, and Goncalves Joana sold 4.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ORKA Key Metrics

Key financial metrics for ORKA
Metric	Value
Price	$60.67
Market Cap	$3.52B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$91.00
52-Week Low	$5.49
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-105.43M
Gross Margin	0.00%

Recent ORKA Insider Trades

Agarwal Arjun sold 4.19K (~$244.47K) on May 18, 2026.
Agarwal Arjun sold 4.60K (~$272.26K) on May 18, 2026.
Agarwal Arjun sold 800 (~$48.27K) on May 18, 2026.
Agarwal Arjun sold 700 (~$42.81K) on May 18, 2026.
Goncalves Joana sold 4.80K (~$295.49K) on May 15, 2026.

Latest ORKA News

Oruka Reports 63.5% PASI 100 Rate and Raises $700M Cash — May 13, 2026
Oruka Therapeutics Prices $700.4M Offer at $72.50 Per Share — Apr 29, 2026
Oruka Therapeutics Files $500M Public Offering with $75M Upsize Option — Apr 27, 2026
Orka Shares Climb 18.9% After 63.5% PASI 100 Trial and $160 Target — Apr 27, 2026
Oruka Therapeutics’ ORKA-001 achieves 63.5% complete skin clearance at week 16 — Apr 27, 2026

ORKA Analyst Consensus

13 analysts cover ORKA: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.25.

Common questions about ORKA

Who is trading ORKA stock inside the company?: Recent ORKA insider activity includes Agarwal Arjun sold 4.19K, Agarwal Arjun sold 4.60K, Agarwal Arjun sold 800, Agarwal Arjun sold 700, and Goncalves Joana sold 4.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ORKA?: Yes. Rallies tracks ORKA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ORKA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ORKA. It does not provide personalized investment advice.